In its Therapeutics Strategy, adopted on Thursday, the Commission says that vaccination rates are increasing across the
EU, but therapeutics are vital to treat those people who are still falling ill and reduce the rate of acute and severe Covid-19. It also includes the treatment of so-called ‘long Covid’.
Authorizing three new therapeutics to treat
Covid-19 by October and possibly two more by end of the year are among the targets set in the strategy. This will be ensured by development of flexible regulatory approaches to speed up the assessment of therapeutics. The only drug for Covid authorized so far is Remdesivir.
Perspectiva científica en clave COVID para después del verano
ultimahora.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ultimahora.es Daily Mail and Mail on Sunday newspapers.
Coronavirus: Commission mobilizes €123 million for research and innovation to combat the threat of variants
eureporter.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eureporter.co Daily Mail and Mail on Sunday newspapers.
EU Monitor
The Commission is mobilising €123 million from Horizon Europe, the new EU i research and innovation programme, for urgent research into coronavirus variants. This first emergency funding under Horizon Europe adds to a range of EU-funded research and innovation actions to fight the coronavirus and contributes to the Commission s overall action to prevent, mitigate and respond to the impact of coronavirus variants, in line with the new European bio-defence preparedness plan HERA Incubator.
Gabriel i, Commissioner for Innovation, Research, Culture, Education and Youth, said:
“We continue to mobilise all means at our disposal to fight this pandemic and the challenges presented by coronavirus variants. We must use our combined strength to be prepared for the future, starting from the early detection of the variants to the organisation and coordination of clinical trials for new vaccines and treatments, while ensuring correct data collection and sharing at all stages.